Radboudumc
Nijmegen, Netherlands
NCT Number: NCT05361499
Infection with Streptococcus pneumoniae (the pneumococcus) is the leading cause of pneumonia, bacterial meningitis and bacteraemia worldwide in the very young and the elderly. Although pneumococcal vaccines exist, they do not provide complete protection and new strategies to combat this pathogen are urgently needed. Asymptomatic infection of S. pneumoniae in the human nasopharynx precedes the development of pneumococcal disease. Previously, an Experimental Human Pneumococcal Carriage (EHPC) model has been developed at the Liverpool School of Tropical Medicine (LSTM). The current study entails to establish this model in healthy adults living in the Netherlands using the inoculation dose currently used at LSTM.
Healthy adult participants (M/F) will be inoculated intranasally with strain BHN418, a penicillin sensitive serotype 6B strain of S. pneumoniae that was previously isolated from a healthy carrier. Following inoculation, participants will be monitored and blood and nasal samples will be collected over a period of 28 ± 3 days. Participants will receive a course of amoxicillin to eradicate infection on or shortly after the last visit at day 28 ± 3, unless S. pneumoniae is not detected on both day 14 and 28 ± 3 post-inoculation.
Looking for future studies?
Notify Me18 year–49 year
All sexes
Interventional
Not applicable
Nijmegen, Netherlands
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intranasal inoculation of Streptococcus pneumoniae serotype 6B, 160,000 colony forming units (CFU)
Amoxicillin, 7 days, 2x 500 mg
Time frame: up to 4 weeks after inoculation
Time frame: from the baseline visit (between day -1 and -6) till the end of the study (day 28 ± 3)
Time frame: from the baseline visit (between day -1 and -6) till the end of the study (day 28 ± 3)
Time frame: On day 3, 7, 14 and 28 after inoculation
Time frame: On day 3, 7, 14 and 28 after inoculation
Time frame: On day 3, 7, 14 and 28 after inoculation
Time frame: On day 3, 7, 14 and 28 after inoculation
Time frame: On day 3, 7, 14 and 28 after inoculation
Time frame: On day 3, 7, 14 and 28 after inoculation
Time frame: On day 3, 7, 14 and 28 after inoculation
Time frame: On day 3, 7, 14 and 28 after inoculation
Time frame: On day 3, 7, 14 and 28 after inoculation
Radboud University Medical Center
Other
Acronym: PIM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05060146
Bacterial Infections, Bacterial Infections and Mycoses
Alès, France
View Trial DetailsNCT05681156
Bacterial Infections, Bacterial Infections and Mycoses
Indianapolis, Indiana, United States
View Trial DetailsNCT03489018
Bacterial Infections, Bacterial Infections and Mycoses
Kilifi, Kenya
View Trial DetailsNCT03384589
Bacterial Infections, Bacterial Infections and Mycoses
Vancouver, British Columbia, Canada
View Trial Details